IMPLANET

- EUR (-)

- 15 min delayed data - Euronext Paris

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	ALIMP
ISIN:	FR0013470168

IMPLANET overview

> News Business Wire published a news.

IMPLANET Reports Revenue of €2.58 Million in Q1 2025, Up +16% • • Business Wire • Stocks • More IMPLANET news...

Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specialized in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its revenue for the first quarter of 2025. Ludovic Lastennet, IMPLANET’s Chief Executive Officer , stated: “We continue on our growth trajectory with a 16% increase in revenue in the first quarter of 2025. This momentum is driven by the sustained development of...

Thank you Chart

> News Business Wire published a news.

IMPLANET Reports Its 2024 Full-Year Results • • Business Wire • Stocks • More IMPLANET news...

Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specialized in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its results for the fiscal year ended December 31, 2024, as approved by the Board of Directors on March 4, 2025. Ludovic Lastennet, IMPLANET’s Chief Executive Officer , stated: “Throughout 2024, we successfully balanced the revitalization of our commercial...

Thank you Chart

> News Business Wire published a news.

IMPLANET Announces 2024 Full-Year Revenue Up 26% to €9.4 Million • • Business Wire • Stocks • More IMPLANET news...

Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its full-year 2024 revenue and cash position as of December 31, 2024. Ludovic Lastennet, IMPLANET’s Chief Executive Officer , stated: “The strong commercial performance achieved in the second half of 2024, with 66% growth compared to the...

Thank you Chart

> News Business Wire published a news.

IMPLANET Announces Its 2025 Financial Calendar • • Business Wire • Stocks • More IMPLANET news...

Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its schedule for the publication of financial information for 2025. Events Dates* 2024 Full-Year Revenue January 14, 2025 2024 Full-Year Results March 4, 2025 Annual General Meeting March 28, 2025 2025 First-Quarter Revenue April 9, 2025...

Thank you Chart

> News Business Wire published a news.

IMPLANET Announces Financing of Around €2 Million • • Business Wire • Stocks • More IMPLANET news...

Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces the implementation of financing with Shanghai Pudong Development Bank ("SPD Bank"). Ludovic Lastennet, IMPLANET’s Chief Executive Officer , stated: “I would like to thank our partners, Sanyou Medical and SPD Bank, for their confidence in...

Thank you Chart

> Analyses

Londinia AI has published a new analysis.

0
93657
15797
0

IMPLANET - Daily

Timeframe : Daily - Simple chart
Status : TARGET REACHED

The bullish trend is currently very strong on IMPLANET. As long as the price remains above the support at 0.1197 EUR, you could try to benefit from the boom. The first bullish objective is located at…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis for pierrott.

0
93657
15797
0

IMPLANET - Daily

Timeframe : Daily - Simple chart
Status : TARGET REACHED

All elements being clearly bullish, it would be possible for traders to trade only long positions (at the time of purchase) on IMPLANET as long as the price remains well above 0.1007 EUR. The buyers'…

Thank you Reply Chart

> News Business Wire published a news.

IMPLANET Reports Revenue of €4.3 Million in the First Half of 2023 • • Business Wire • Stocks • More IMPLANET news...

Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of technological medical equipment, today announced its revenue for the first half of 2023. Ludovic Lastennet, IMPLANET’s CEO , stated: “ Implanet recorded stable revenue in the first half of 2023 compared with the same period of 2022, but the semester was marked by determined...

Thank you Chart

Load more content

Market scanning tools

See all Signals

Statistics

Analyses : 75
Followers : 8